Back to search

Netherlands· NL-20fc1d0e3ba4

KAYFANDA 1200 microgram harde capsules

A odevixibat product containing odevixibat 1,5-water, registered in Netherlands by Ipsen Pharma. The same ATC class is registered in 15 of our 19 countries.

ATC A05AX05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedKAYFANDA 1200 microgram harde capsulesATCA05AX05REGISTER NO.NL-20fc1d0e3ba4PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Odevixibat is registered in 15 of 19 countries.

Countries holding a registration under ATC A05AX05 (odevixibat), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Odevixibat · ATC A05AX05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ODEVIXIBAT 1,5-WATER
Manufacturer
Ipsen Pharma
Country
Netherlands (NL)
ATC code
A05AX05
ATC class
Odevixibat
Defined daily dose
2.4 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1854

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Odevixibat in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All odevixibat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Bylvay, Kayfanda
  • Liechtenstein · Bylvay, Kayfanda
  • Norway · Bylvay, Kayfanda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f46f37aa-3764-4928-b5ca-acee3411f0ad
GET /v1/drugs/f46f37aa-3764-4928-b5ca-acee3411f0ad?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kayfanda-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Odevixibat",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132747",
  "excipients": [
    "AMMONIA (E 527)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "ODEVIXIBAT 1,5-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/09/19",
  "procedure_number": "EMEA/H/C/006462",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1854",
  "additional_monitoring": "Y"
}

See everything about odevixibat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.